Literature DB >> 28040793

TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma.

Fabienne Brügger1, Matthias S Dettmer1, Maja Neuenschwander1, Aurel Perren1, Ilaria Marinoni1, Ekkehard Hewer1.   

Abstract

Genetic signatures related to telomere maintenance have emerged as powerful classifiers among CNS tumors. These include the alternative lengthening of telomeres (ALT) phenotype associated with mutations in the ATRX and DAXX genes and recurrent point mutations in the TERT gene promoter. We investigated a patient cohort covering the entire spectrum of childhood and adult ependymomas (n = 128), including subependymomas and myxopapillary ependymomas, for the presence of TERT promoter mutations, for loss of ATRX or DAXX expression by immunohistochemistry (as surrogates as underlying gene mutations), and for the ALT phenotype by fluorescence in situ hybridization (FISH). TERT promoter mutations were identified in 9/120 (7%) of tumors, all of which were conventional ependymomas occurring in adults. TERT promoter mutations were associated with older age and intracranial localization. Remarkably, 2 of these tumors progressed to ependymosarcoma upon recurrence. No tumors displayed an ALT phenotype by FISH or were ATRX or DAXX deficient by immunohistochemistry. In sum, TERT promoter mutations are present in a subset of mostly intracranial conventional ependymomas in adults and may be relevant for the uncommon progression to ependymosarcoma. Loss of ATRX immunoreactivity is a useful marker to rule out ependymoma in specific diagnostic settings.
© 2017 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  ATRX; Alternative lengthening of telomeres; DAXX; Ependymoma; Ependymosarcoma; TERT

Mesh:

Substances:

Year:  2017        PMID: 28040793     DOI: 10.1093/jnen/nlw106

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  4 in total

1.  Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.

Authors:  Ekkehard Hewer; Nadine Prebil; Sabina Berezowska; Marielena Gutt-Will; Philippe Schucht; Matthias S Dettmer; Erik Vassella
Journal:  Virchows Arch       Date:  2017-08-19       Impact factor: 4.064

2.  Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Squamous Cell Carcinomas Identifies KMT2C as a Potential Tumor Suppressor.

Authors:  Marcin M Machnicki; Anna Rzepakowska; Joanna I Janowska; Monika Pepek; Alicja Krop; Katarzyna Pruszczyk; Piotr Stawinski; Malgorzata Rydzanicz; Jakub Grzybowski; Barbara Gornicka; Maciej Wnuk; Rafal Ploski; Ewa Osuch-Wojcikiewicz; Tomasz Stoklosa
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

3.  Differential Regulation of Telomeric Complex by BCR-ABL1 Kinase in Human Cellular Models of Chronic Myeloid Leukemia-From Single Cell Analysis to Next-Generation Sequencing.

Authors:  Anna Deregowska; Monika Pepek; Katarzyna Pruszczyk; Marcin M Machnicki; Maciej Wnuk; Tomasz Stoklosa
Journal:  Genes (Basel)       Date:  2020-09-29       Impact factor: 4.096

4.  Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma.

Authors:  Chenan Zhang; Quinn T Ostrom; Eleanor C Semmes; Vijay Ramaswamy; Helen M Hansen; Libby Morimoto; Adam J de Smith; Melike Pekmezci; Zalman Vaksman; Hakon Hakonarson; Sharon J Diskin; Catherine Metayer; Michael D Taylor; Joseph L Wiemels; Melissa L Bondy; Kyle M Walsh
Journal:  Acta Neuropathol Commun       Date:  2020-10-28       Impact factor: 7.578

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.